(IRON) Disc Medicine - Overview
Sector: HealthcareIndustry: Biotechnology | Exchange NASDAQ (USA) | Currency USD | Market Cap: 2.220m | Total Return 18.5% in 12m
Stock: Blood Disorders, Drug Development, Clinical Trials, Red Blood Cells
Total Rating 31
Risk 80
Buy Signal -0.58
| Risk 5d forecast | |
|---|---|
| Volatility | 58.3% |
| Relative Tail Risk | -8.31% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.52 |
| Alpha | -2.11 |
| Character TTM | |
|---|---|
| Beta | 1.250 |
| Beta Downside | 0.479 |
| Drawdowns 3y | |
|---|---|
| Max DD | 64.79% |
| CAGR/Max DD | 0.66 |
Risks
Technicals:
choppy
Description: IRON Disc Medicine March 04, 2026
Disc Medicine Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for hematologic diseases. The companys pipeline includes candidates targeting red blood cell formation and iron regulation.
The companys lead product candidate, bitopertin, addresses erythropoietic porphyrias and Diamond-Blackfan Anemia. DISC-0974 is in development for anemia associated with myelofibrosis and chronic kidney disease, while DISC-3405 targets polycythemia vera and other blood disorders.
The biotechnology sector is characterized by high research and development costs and a long drug development timeline. The companys business model relies on the successful progression of drug candidates through clinical trials to potential commercialization.
Investors may wish to further explore Disc Medicines clinical trial results and market potential on ValueRay.
Headlines to watch out for
- Clinical trial results for bitopertin impact stock valuation
- DISC-0974 regulatory approval drives revenue forecasts
- Pipeline expansion into new hematologic disorders fuels growth
- Competition from other biopharmaceutical companies affects market share
- Research and development expenses influence profitability
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -212.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.22 > 0.02 and ΔFCF/TA -3.46 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.22 > 3% & CFO -180.4m > Net Income -212.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 21.94 > 1.5 & < 3 |
| Outstanding Shares: last quarter (35.3m) vs 12m ago 17.91% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: -1.84% > 50% (prev 0.0%; Δ -1.84% > 0%) |
| Interest Coverage Ratio: -45.75 > 6 (EBITDA TTM -207.1m / Interest Expense TTM 4.53m) |
Altman Z'' -5.93
| A: 0.95 (Total Current Assets 803.9m - Total Current Liabilities 36.6m) / Total Assets 806.9m |
| B: -0.63 (Retained Earnings -510.2m / Total Assets 806.9m) |
| C: -0.32 (EBIT TTM -207.3m / Avg Total Assets 651.8m) |
| D: -7.59 (Book Value of Equity -509.2m / Total Liabilities 67.1m) |
| Altman-Z'' Score: -5.93 = D |
Beneish M
| DSRI: none (Receivables none/none, Revenue -12.0m/0.0) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.53 (AQ_t 0.00 / AQ_t-1 0.00) |
| SGI: none (Revenue -12.0m / 0.0) |
| TATA: -0.04 (NI -212.2m - CFO -180.4m) / TA 806.9m) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of IRON shares?
As of March 26, 2026, the stock is trading at USD 62.55 with a total of 466,806 shares traded.
Over the past week, the price has changed by +5.77%, over one month by -6.49%, over three months by -22.13% and over the past year by +18.49%.
Over the past week, the price has changed by +5.77%, over one month by -6.49%, over three months by -22.13% and over the past year by +18.49%.
Is IRON a buy, sell or hold?
Disc Medicine has received a consensus analysts rating of 4.73.
Therefore, it is recommended to buy IRON.
- StrongBuy: 8
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the IRON price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 100.2 | 60.1% |
| Analysts Target Price | 100.2 | 60.1% |
IRON Fundamental Data Overview March 24, 2026
P/B = 3.0001
Revenue TTM = -12.0m USD
EBIT TTM = -207.3m USD
EBITDA TTM = -207.1m USD
Long Term Debt = 29.2m USD (from longTermDebt, last quarter)
Short Term Debt = 611k USD (from shortTermDebt, last quarter)
Debt = 1.86m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -89.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.43b USD (2.22b + Debt 1.86m - CCE 791.2m)
Interest Coverage Ratio = -45.75 (Ebit TTM -207.3m / Interest Expense TTM 4.53m)
EV/FCF = -7.89x (Enterprise Value 1.43b / FCF TTM -181.3m)
FCF Yield = -12.68% (FCF TTM -181.3m / Enterprise Value 1.43b)
WARNING: Negative Revenue TTM = -12.0m
FCF Margin = 1.51k% (FCF TTM -181.3m / Revenue TTM -12.0m)
WARNING: Negative Revenue TTM = -12.0m
Net Margin = 1.77k% (Net Income TTM -212.2m / Revenue TTM -12.0m)
WARNING: Negative Revenue TTM = -12.0m
Gross Margin = unknown ((Revenue TTM -12.0m - Cost of Revenue TTM 281k) / Revenue TTM)
Tobins Q-Ratio = 1.77 (Enterprise Value 1.43b / Total Assets 806.9m)
Interest Expense / Debt = 96.96% (Interest Expense 1.81m / Debt 1.86m)
Taxrate = 21.0% (US default 21%)
NOPAT = -163.8m (EBIT -207.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 21.94 (Total Current Assets 803.9m / Total Current Liabilities 36.6m)
Debt / Equity = 0.00 (Debt 1.86m / totalStockholderEquity, last quarter 739.8m)
Debt / EBITDA = 0.43 (negative EBITDA) (Net Debt -89.3m / EBITDA -207.1m)
Debt / FCF = 0.49 (negative FCF - burning cash) (Net Debt -89.3m / FCF TTM -181.3m)
Total Stockholder Equity = 646.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -32.55% (Net Income -212.2m / Total Assets 806.9m)
RoE = -32.80% (Net Income TTM -212.2m / Total Stockholder Equity 646.9m)
RoCE = -30.66% (EBIT -207.3m / Capital Employed (Equity 646.9m + L.T.Debt 29.2m))
RoIC = -24.23% (negative operating profit) (NOPAT -163.8m / Invested Capital 675.8m)
WACC = 10.37% (E(2.22b)/V(2.22b) * Re(10.38%) + (debt cost/tax rate unavailable))
Discount Rate = 10.38% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 22.39%
[DCF] Fair Price = unknown (Cash Flow -181.3m)
EPS Correlation: -5.08 | EPS CAGR: 117.9% | SUE: 0.50 | # QB: 0
Revenue Correlation: -11.39 | Revenue CAGR: -47.24% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-1.79 | Chg7d=-0.055 | Chg30d=-0.103 | Revisions Net=-5 | Analysts=10
EPS current Year (2026-12-31): EPS=-7.34 | Chg7d=-0.237 | Chg30d=-0.727 | Revisions Net=-8 | Growth EPS=-22.1% | Growth Revenue=+0.0%
EPS next Year (2027-12-31): EPS=-7.52 | Chg7d=-0.321 | Chg30d=-2.305 | Revisions Net=-9 | Growth EPS=-2.4% | Growth Revenue=+0.0%
[Analyst] Revisions Ratio: -0.71 (1 Up / 6 Down within 30d for Next Quarter)
Revenue TTM = -12.0m USD
EBIT TTM = -207.3m USD
EBITDA TTM = -207.1m USD
Long Term Debt = 29.2m USD (from longTermDebt, last quarter)
Short Term Debt = 611k USD (from shortTermDebt, last quarter)
Debt = 1.86m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -89.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.43b USD (2.22b + Debt 1.86m - CCE 791.2m)
Interest Coverage Ratio = -45.75 (Ebit TTM -207.3m / Interest Expense TTM 4.53m)
EV/FCF = -7.89x (Enterprise Value 1.43b / FCF TTM -181.3m)
FCF Yield = -12.68% (FCF TTM -181.3m / Enterprise Value 1.43b)
WARNING: Negative Revenue TTM = -12.0m
FCF Margin = 1.51k% (FCF TTM -181.3m / Revenue TTM -12.0m)
WARNING: Negative Revenue TTM = -12.0m
Net Margin = 1.77k% (Net Income TTM -212.2m / Revenue TTM -12.0m)
WARNING: Negative Revenue TTM = -12.0m
Gross Margin = unknown ((Revenue TTM -12.0m - Cost of Revenue TTM 281k) / Revenue TTM)
Tobins Q-Ratio = 1.77 (Enterprise Value 1.43b / Total Assets 806.9m)
Interest Expense / Debt = 96.96% (Interest Expense 1.81m / Debt 1.86m)
Taxrate = 21.0% (US default 21%)
NOPAT = -163.8m (EBIT -207.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 21.94 (Total Current Assets 803.9m / Total Current Liabilities 36.6m)
Debt / Equity = 0.00 (Debt 1.86m / totalStockholderEquity, last quarter 739.8m)
Debt / EBITDA = 0.43 (negative EBITDA) (Net Debt -89.3m / EBITDA -207.1m)
Debt / FCF = 0.49 (negative FCF - burning cash) (Net Debt -89.3m / FCF TTM -181.3m)
Total Stockholder Equity = 646.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -32.55% (Net Income -212.2m / Total Assets 806.9m)
RoE = -32.80% (Net Income TTM -212.2m / Total Stockholder Equity 646.9m)
RoCE = -30.66% (EBIT -207.3m / Capital Employed (Equity 646.9m + L.T.Debt 29.2m))
RoIC = -24.23% (negative operating profit) (NOPAT -163.8m / Invested Capital 675.8m)
WACC = 10.37% (E(2.22b)/V(2.22b) * Re(10.38%) + (debt cost/tax rate unavailable))
Discount Rate = 10.38% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 22.39%
[DCF] Fair Price = unknown (Cash Flow -181.3m)
EPS Correlation: -5.08 | EPS CAGR: 117.9% | SUE: 0.50 | # QB: 0
Revenue Correlation: -11.39 | Revenue CAGR: -47.24% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-1.79 | Chg7d=-0.055 | Chg30d=-0.103 | Revisions Net=-5 | Analysts=10
EPS current Year (2026-12-31): EPS=-7.34 | Chg7d=-0.237 | Chg30d=-0.727 | Revisions Net=-8 | Growth EPS=-22.1% | Growth Revenue=+0.0%
EPS next Year (2027-12-31): EPS=-7.52 | Chg7d=-0.321 | Chg30d=-2.305 | Revisions Net=-9 | Growth EPS=-2.4% | Growth Revenue=+0.0%
[Analyst] Revisions Ratio: -0.71 (1 Up / 6 Down within 30d for Next Quarter)